Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s share price shot up 11% during trading on Tuesday . The company traded as high as $10.39 and last traded at $9.99, with a volume of 125,369 shares. The stock had previously closed at $9.00.

A number of research firms recently commented on SYRS. HC Wainwright began coverage on Syros Pharmaceuticals in a research note on Monday, July 18th. They issued a “neutral” rating and a $10.00 price objective on the stock. Cowen and Company began coverage on Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating on the stock. JMP Securities began coverage on Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating and a $22.00 price objective on the stock. Wedbush began coverage on Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating and a $18.00 price objective on the stock. Finally, Piper Jaffray Cos. began coverage on Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “overweight” rating and a $20.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Syros Pharmaceuticals currently has an average rating of “Buy” and an average price target of $17.50.

The firm’s market cap is $272.54 million. The stock’s 50-day moving average is $0.00 and its 200 day moving average is $0.00.

In other news, major shareholder Redmile Group, Llc acquired 432,746 shares of Syros Pharmaceuticals stock in a transaction dated Wednesday, July 6th. The shares were purchased at an average cost of $12.50 per share, for a total transaction of $5,409,325.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Robert Nelsen acquired 400,000 shares of Syros Pharmaceuticals stock in a transaction dated Wednesday, July 6th. The shares were purchased at an average price of $12.50 per share, for a total transaction of $5,000,000.00. The disclosure for this purchase can be found here.

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.